Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2008 Mar 17;22(2):138–145. doi: 10.1002/jcla.20231

Preliminary clinical measurement of the expression of TNF‐related apoptosis inducing ligand in patients with ankylosing spondylitis

Yang Zai‐Xing 1,†, Liang Yan 1,‡, Wang Hao 1, Zhu Ye 1, Li Chang 1, Zhong Ren‐Qian 1,✉
PMCID: PMC6649006  PMID: 18348311

Abstract

It has recently been reported that tumor necrosis factor (TNF)‐related apoptosis inducing ligand (TRAIL) plays various roles in such autoimmune diseases as diabetes, multiple sclerosis (MS), and systemic lupus erythematosus (SLE). However, it has still remained unclear whether there is a close relationship between TRAIL and ankylosing spondylitis (AS). In this study, we investigated the association between the expression of TRAIL and AS. The specific messenger ribonucleic acid (mRNA) levels of TRAIL in peripheral blood mononuclear cells (PBMCs), serum sTRAIL, and TNF‐α concentrations from 60 AS patients, 20 rheumatoid arthritis (RA) patients, and 30 healthy controls were determined by real‐time fluorescent quantitative polymerase chain reaction (PCR) and enzyme‐linked immunosorbent assay (ELISA). The results indicated that the expression levels of TRAIL mRNA, and serum sTRAIL were significantly elevated in AS patients, compared with RA patients and healthy controls, and there was a close association between TRAIL mRNA and sTRAIL levels. However, there was no significant difference between human leukocyte antigen (HLA)‐B27‐positive and ‐negative AS patients. In HLA‐B27‐positive patients, TRAIL mRNA and sTRAIL closely correlated with serum TNF‐α and C‐reactive protein (CRP), but did not correlate in HLA‐B27‐negative patients. In conclusion, upregulated expression of TRAIL might be somewhat specific for evaluation of AS. J. Clin. Lab. Anal. 22:138–145, 2008. © 2008 Wiley‐Liss, Inc.

Keywords: ankylosing spondylitis, rheumatoid arthritis, TNF‐related apoptosis inducing ligand, TNF‐α

REFERENCES

  • 1. Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factorα. N Engl J Med 2002;346:1349–1358. [DOI] [PubMed] [Google Scholar]
  • 2. Davis JC, van der Heijde DM, Braun J, Dougados M, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005;64:1557–1562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002;61(Suppl III):8–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Gratacos J, Collado A, Filella X, et al. Serum cytokines (IL‐6, TNF‐α, IL‐1β and IFN‐γ) in ankylosing spondylitis: a close correlation between serum IL‐6 and disease activity and severity. Br J Rheumatol 1994;33:927–931. [DOI] [PubMed] [Google Scholar]
  • 5. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499–505. [DOI] [PubMed] [Google Scholar]
  • 6. Davis JC. Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis. Semin Arthritis Rheum 2004;34:668–677. [DOI] [PubMed] [Google Scholar]
  • 7. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double‐blind, placebo‐controlled trial. Arthritis Rheum 2006;54:2136–2146. [DOI] [PubMed] [Google Scholar]
  • 8. Zauli G, Secchiero P. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 2006;17:245–257. [DOI] [PubMed] [Google Scholar]
  • 9. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673–682. [DOI] [PubMed] [Google Scholar]
  • 10. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo‐2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687–12690. [DOI] [PubMed] [Google Scholar]
  • 11. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673–682. [DOI] [PubMed] [Google Scholar]
  • 12. LeBlanc HN, Ashkenazi A. Apo 2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66–75. [DOI] [PubMed] [Google Scholar]
  • 13. Wandinger KP, Lunemann JD, Wengert O, et al. TNF‐related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon‐beta treatment in multiple sclerosis. Lancet 2003;361:2036–2043. [DOI] [PubMed] [Google Scholar]
  • 14. Lub‐de Hooge MN, de Vries EGE, de Jong S, Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:854–858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Morel J, Audo R, Hahne M, Combe B. Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen‐activated protein kinases and phosphatidylinositol 3‐Kinase/Akt. J Biol Chem 2005;280:15709–15718. [DOI] [PubMed] [Google Scholar]
  • 16. Yang ZX, Liang Y, Zhu Y, et al. Increased expression of Toll‐like receptor 4 in peripheral blood leucocytes and serum levels of some cytokines in patients with ankylosing spondylitis. Clin Exp Immunol 2007;149:48–55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–368. [DOI] [PubMed] [Google Scholar]
  • 18. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–324. [DOI] [PubMed] [Google Scholar]
  • 19. Lamhamedi‐Cherradi SE, Zheng SJ, Maguschak KA, Peschon J, Chen YH. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL –/– mice. Nat Immunol 2003;4:255–260. [DOI] [PubMed] [Google Scholar]
  • 20. Lamhamedi‐Cherradi SE, Zheng S, Tisch RM, Chen YH. Critical roles of tumor necrosis factor‐related apoptosis‐inducing ligand in type 1 diabetes. Diabetes 2003;52:2274–2278. [DOI] [PubMed] [Google Scholar]
  • 21. Cretney E, McQualter JL, Kayagaki N, et al. TNF‐related apoptosis‐inducing ligand (TRAIL)/Apo 2L suppresses experimental autoimmune encephalomyelitis in mice. Immunol Cell Biol 2005;83:511–519. [DOI] [PubMed] [Google Scholar]
  • 22. Aktas O, Smorodchenko A, Brocke S, et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 2005;46:421–432. [DOI] [PubMed] [Google Scholar]
  • 23. Morel J, Audo R, Hahne M, Combe B. Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen‐activated protein kinases and phosphatidylinositol 3‐kinase/Akt. J Biol Chem 2005;280:15709–15718. [DOI] [PubMed] [Google Scholar]
  • 24. Song BK, Chen YG, Goke R, et al. Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 2000;7:1095–1103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004;63:535–543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Freeston J, Barkham N, Hensor E, Emery P, Fraser A. Ankylosing spondylitis, HLA‐B27 positivity and the need for biologic therapies. Joint Bone Spine 2007;74:140–143. [DOI] [PubMed] [Google Scholar]
  • 27. Wandinger KP, Lunemann JD, Wengert O, et al. TNF‐related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon‐beta treatment in multiple sclerosis. Lancet 2003;361:2036–2043. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES